471 results about "Antitumor therapy" patented technology

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.

The invention discloses an application of nanometer structure lipid carrier administration system in the antineoplastic drug to reverse the multiple-drug tolerance of tumour cell, which comprises the following parts: solid lipid material, liquid lipid material and antineoplastic drug, wherein the rate of the liquid lipid (such as oleic acid) is 0-30wt%; the solid lipid is selected from monoglyceride; the liquid lipid is oleic acid; the antineoplastic drug is Paclitaxel or adriablastina. The invention has highly effective cell uptaking and cytolymph condensing function with packing molecular target in the antineoplastic drug of cell, which avoids P-glucoprotein in the drug tolerant cytolymph from identifying the antineoplastic drug to reduce exclusion.

The present invention relates to methods of using whole glucan particles and complement activating antibodies for antitumor therapy. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines.

An internal dry powder delivery system through a working channel of an endoscopic cannula for directly applying the powder form medication to an internal tissue/organ site, includes an elongated tubular delivery channel and a powder supply device for producing pressurized gas mixing with the dry powder for feeding to form a mixture of dry powder and pressurized gas delivering to an internal tissue/organ site through the delivery channel via endoscopic cannula. It ensures a smooth powder release by preventing liquid from accumulation at the tip of the delivery channel and offers physicians a new powder form drug delivery method via endoscope. Also, it offers new minimal invasive application by directly and precisely applying the powder format drug to the internal sites of human gastrointestinal organ via endoscope to achieve hemostasis, anti-inflammation, anti-ulcer and anti-tumor treatment, etc.

The invention belongs to the field of pharmaceutical agents, relates to a polymer micelle lyophilized agent encapsulating an insoluble antitumor drug as well as a preparation method and an application thereof. The polymer micelle lyophilized agent is prepared by carrying out molecular self-assembly on a methoxy poly(ethylene glycol) 2000-polyester block copolymer to form micelles, and then encapsulating the insoluble antitumor drug in a hydrophobic core formed by the polyester. The lyophilized agent has high encapsulation rate, high drug loading and small particle size, can significantly improve the water solubility of the insoluble drug and result in passive targeting of more antitumor drugs to concentrate in the tumor tissues, thus improving an anti-tumor treatment effect and reducing the toxic and side effects of drugs, and can be used to prepare the drugs used for the treatment of lung cancer, intestinal cancer, mammary cancer, ovarian cancer, etc. The lyophilized agent can also be quickly dissolved and dispersed to form a transparent micellar solution after water for injection, normal saline solution and the like are added, and is used for the preparation of the drugs for treating primary intestinal cell carcinoma.

Disclosed are methods and compositions comprising native, site-specifically mutagenized, and synthetic peptides comprising portions of the human estrogen receptor, or estrogen receptor co-activator, and nucleic acid compositions encoding these polypeptide compositions. Also disclosed are methods for synthesizing phosphotyrosyl and malonyltyrosyl peptide derivatives and their use as antiestrogen compositions in the treatment of breast cancers, the preparation of pharmaceutical compositions, diagnostic kits, and the development of related assays for use in antitumor therapies.

Administration of a cruciferous indole compound can reduce undesirable toxic side effects inherent in the anti-tumor therapy with ET-743 before during or after administration of the ET-743.

The invention relates to a dual-sensitivity amphiphilic polysaccharide-doxorubicin conjugate.According to the conjugate, hydrophobic antitumor drug doxorubicin is introduced in a polysaccharide framework through a connecting arm containing a disulfide bond and a hydrazone bond, so that the polysaccharide-doxorubicin conjugate has an amphiphilic property, can be self-assembled into a nano-micelle in water and directly used for tumor treatment, and can also be physically loaded with an antitumor drug to be used for antitumor treatment.The conjugate is mainly characterized in that after the nano-micelle reaches a focus, the disulfide bond in the connecting arm can be degraded specifically by high-concentration reduction substances in focus cells, and meanwhile the hydrazone bond in the connecting arm can be degraded in a special pH environment of the focus, so that the micelle is degraded, the drug is quickly released, and the treatment effect is improved; the antitumor drug is loaded in two modes of chemical conjugation and physical package, and therefore the joint treatment effect is achieved.The polysaccharide conjugate and a pharmaceutical composition can be used for injection or oral administration or external administration, can remarkably improve antitumor activity, and provides a new thought for development of the antitumor drug.

The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.

The invention relates to an embedded antigen receptor based on CD30 and application thereof, and particularly relates to a building method of an embedded antigen receptor T (CAR-T) cell technology based on a tumor specific target site CD30 and application thereof in anti-tumor treatment. The embedded antigen receptor is prepared by connecting an antigen binding structural domain, a transmembrane structural domain, a costimulatory signal conducting region and a CD3 zeta signal conducting structural domain in series, wherein the antigen binding structural domain is combined with tumor-surface antigen, and the tumor-surface antigen is CD30. By adopting the embedded antigen receptor, specific gene transformation on a single chain antibody of the tumor-surface antigen CD30 is carried out, and because of the transformed antibody, the binding force of the antigen-antibody is stronger, and the mutation difficultly occurs; compared with other embedded antigen receptors and other tumor antigens, the embedded antigen receptor has a better effect, and the expression quantity of the target site is high, so that an immunization effect of CAR-T cells is enhanced, and a treatment effect on the CAR-T cells is enhanced.

Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.

The invention relates to an embedded antigen receptor based on CD22 and application thereof, and particularly relates to a building method of an embedded antigen receptor T (CAR-T) cell technology based on a tumor specific target site CD22 and application thereof in anti-tumor treatment. The embedded antigen receptor is prepared by connecting an antigen binding structural domain, a transmembrane structural domain, a costimulatory signal conducting region and a CD3 zeta signal conducting structural domain in series, wherein the antigen binding structural domain is combined with tumor-surface antigen, and the tumor-surface antigen is CD22. By adopting the embedded antigen receptor, specific gene transformation on a single chain antibody of the tumor-surface antigen CD22 is carried out, and because of the transformed antibody, the binding force of the antigen-antibody is stronger, and the mutation difficultly occurs; compared with other embedded antigen receptors and other tumor antigens, the embedded antigen receptor has a better effect, and the expression quantity of the target site is high, so that an immunization effect of CAR-T cells is enhanced, and a treatment effect on the CAR-T cells is enhanced.

The invention discloses new medicinal uses of chlorogenic acid, especially uses of chlorogenic acid in preparation of drugs treating multidrug resistance of cancer, and provides uses of chlorogenic acid and antitumor drugs in preparation of drugs treating cancer. By inhibiting activity and expression of drug pump protein on surfaces of tumor cells, tumor patients generating multidrug resistance can receive durable and effective treatment. A combination of the chlorogenic acid and a drug-resistant drug is provided, thus alleviating or eliminating drug resistance to multiple drugs for patients, allowing patients with drug resistance to receive durable and effective treatment, and overcoming the limitation problem at present that tumor patients cannot receive durable and effective treatment due to generation of drug resistance. The uses have important meaning in clinical use of antitumor treatment.

Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.

The present invention relates to methods for prognosis, diagnosis, and treatment of malignant tumors that were treatment resistant. The present invention provides methods of prognosis and diagnosis of multidrug resistant tumors through detection of the expression levels of nuclear co-repressor 2 (“N-CoR2”), histone deacetylases 3 (“HDAC3”), and their associated gene expression biomarkers. The present invention also provides methods of sensitizing tumors to anti-tumor therapeutics by disrupting HDAC3 activation, abrogating the N-CoR2-HDAC3 interaction, inhibiting the activity of either protein, or by down-regulating the expression of either protein.